You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 10, October 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cognitive-Behavioral and Pharmacological Treatments of Social Phobia

A Controlled Study

Cheryl Shea Gelernter, PhD; Thomas W. Uhde, MD; Peter Cimbolic, PhD; Diane B. Arnkoff, PhD; Bernard J. Vittone, MD; Manuel E. Tancer, MD; John J. Bartko, PhD

Arch Gen Psychiatry. 1991;48(10):938-945.


Abstract

• Sixty-five patients with social phobia were treated in a study that compared a cognitive-behavioral group treatment program with pharmacotherapy with alprazolam, phenelzine sulfate, or pill-placebo plus instructions for self-directed exposure to phobic stimuli. Statistically significant repeated-measures effects were shown on all measures, indicating that the treatments studied were associated with substantial improvements in patients with severe and chronic social phobia. Patients who were treated with phenelzine were rated by clinicians as more improved on a measure of work and social disability than patients who were treated with alprazolam or placebo (patients in the cognitive-behavior therapy group were not rated on this measure). Subjects showed positive cognitive changes from before to after treatment, and there were no differences between treatment groups on the cognitive measure. We discuss the implications of these findings within the context of demographic and clinical predictors of response.



Author Affiliations

From the Section on Anxiety and Affective Disorders, Biological Psychiatry Branch (Drs Gelernter, Uhde, Vittone, and Tancer) and Division of Biometry and Applied Sciences (Dr Bartko), National Institute of Mental Health, Bethesda, Md, and the Counseling Center (Dr Cimbolic) and Department of Psychology (Dr Arnkoff), The Catholic University of America, Washington, DC. Dr Gelernter is now a research associate, Genetic Epidemiology Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, Conn.


Footnotes

Accepted for publication February 14, 1991.

Reprint requests to Section on Anxiety and Affective Disorders, Biological Psychiatry Branch, National Institute of Mental Health, 9000 Rockville Pike, Bldg 10, Room 3S-239, Bethesda, MD 20892 (Dr Uhde).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Update on the Assessment, Diagnosis, and Treatment of Individuals with Social Anxiety Disorder
Delong and Pollack
Focus 2008;6:431-437.
ABSTRACT | FULL TEXT  

A Randomized Controlled Effectiveness Trial of Acceptance and Commitment Therapy and Cognitive Therapy for Anxiety and Depression
Forman et al.
Behav Modif 2007;31:772-799.
ABSTRACT  

Clinical practice. Social anxiety disorder.
Schneier
NEJM 2006;355:1029-1036.
FULL TEXT  

Venlafaxine Extended Release vs Placebo and Paroxetine in Social Anxiety Disorder
Liebowitz et al.
Arch Gen Psychiatry 2005;62:190-198.
ABSTRACT | FULL TEXT  

The Cognitive-Behavioral Treatment of Social Phobia
Feeney
Clinical Case Studies 2004;3:124-146.
ABSTRACT  

Genome-Wide Linkage Scan for Loci Predisposing to Social Phobia: Evidence for a Chromosome 16 Risk Locus
Gelernter et al.
Am. J. Psychiatry 2004;161:59-66.
ABSTRACT | FULL TEXT  

Behavioral Activation as an Intervention for Coexistent Depressive and Anxiety Symptoms
Hopko et al.
Clinical Case Studies 2004;3:37-48.
ABSTRACT  

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial
HAUG et al.
Br. J. Psychiatry 2003;182:312-318.
ABSTRACT | FULL TEXT  

Efficacy of olanzapine in social anxiety disorder: a pilot study
Barnett et al.
J Psychopharmacol 2002;16:365-368.
ABSTRACT  

Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study
Van Ameringen et al.
Am. J. Psychiatry 2001;158:275-281.
ABSTRACT | FULL TEXT  

The treatment of social phobia in general practice. Is exposure therapy feasible?
Haug et al.
Fam Pract 2000;17:114-118.
ABSTRACT | FULL TEXT  

Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study
Stein et al.
Am. J. Psychiatry 1999;156:756-760.
ABSTRACT | FULL TEXT  

Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg et al.
Arch Gen Psychiatry 1998;55:1133-1141.
ABSTRACT | FULL TEXT  

Advances in the Psychosocial Treatment of Anxiety Disorders: Implications for National Health Care
Barlow and Lehman
Arch Gen Psychiatry 1996;53:727-735.
ABSTRACT  

Behavioral Assessment and Treatment of Social Phobia: An Evaluative Review
Donohue et al.
Behav Modif 1994;18:262-288.
ABSTRACT  

Psychiatry
Freedman and Stahl
JAMA 1992;268:403-405.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.